Journal of Clinical Oncology
Articles in this Issue
Age-dependent pathogenic variant risk in female breast cancer.
1624 Background: Germline pathogenic and likely pathogenic variants (GPVs) in BRCA1...
County-level palliative care physician density and socioeconomic determinants of place of cancer death in the United States, 2021-2023.
12032 Background: Palliative care, a specialized approach focused on care for individuals with serious illness including c...
Association of neoadjuvant therapy with perineural invasion and postoperative survival in locally advanced colon cancer.
e15634 Background: Perineural invasion (PNI) is a marker of aggressive tumor biology and adverse prognosis in colon cancer...
TTFields with maintenance temozolomide (TMZ) and pembrolizumab versus TTFields with maintenance TMZ and placebo for newly diagnosed glioblastoma: The phase 3 EF-41/KEYNOTE D58 trial.
TPS2096 Background: Glioblastoma remains a lethal disease with limited treatment options. With current standard-of-care, c...
Associations between self-efficacy and symptom burden in young women with breast cancer initiating endocrine therapy (ET) on SWOG S2010.
521 Background: Self-efficacy (SE) is the belief in one's ability to succeed in specific situations or accomplish a task,...
When autoimmunity meets immunotherapy: Immune checkpoint inhibitors in cancer patients with rheumatoid arthritis.
11168 Background: Immune checkpoint inhibitors (ICIs) improve outcomes across multiple malignancies but are associated wit...
Real-world experience of cancer patients with clonal hematopoiesis in an urban county hospital system.
e18630 Background: Clonal hematopoiesis (CH), including CH of indeterminate potential (CHIP) and clonal cytopenia of undet...
Physician preferences in large language models for breast cancer management.
e12555 Background: As large language models (LLMs) are increasingly used as decision-support tools in breast oncology, the...
Phase III trial of brain MRI surveillance in stage IV breast cancer.
TPS1160 Background: The incidence and prevalence of breast cancer patients who develop brain metastasis is increasing. Int...
The California End of Life Option Act: A case series of 77 consecutive cancer patients.
e24041 Background: California is 1 of 10 US states with legalized medical assistance in dying for the terminally ill. Ther...
Management of pulmonary nodules across Latin America: A real-world observational study.
8030 Background: Lung cancer is the leading cause of cancer-related mortality globally, with lung cancer accounting for 6....
Knowledge distillation for pancreatic cancer diagnosis: EfficientNet-based deep learning for stage stratification with real-world deployment optimization.
4217 Background: Pancreatic cancer is among the most lethal malignancies, with a 5-year survival below 12%. Prognosis is s...
Optimization of geospatial oncologist placement: A maximum coverage problem approach.
1609 Background: Rural communities in the United States (US) experience persistent shortfalls accessing oncology care due...
Development and validation of an artificial intelligence–based deep learning imaging model for early lung cancer detection: DAVINCI, a retrospective study of 8,962 patients.
8021 Background: Lung cancer is the leading cause of cancer-related mortality worldwide, primarily due to delayed diagnosi...
Are all tumor-agnostic biomarkers equally tissue-independent? Comparative cross-histology efficacy analysis of MSI-H/dMMR versus <i>BRAF</i> V600E.
2649 Background: FDA tumor-agnostic approvals for pembrolizumab/dostarlimab (MSI-H/dMMR) and dabrafenib-trametinib (BRAF V...
Responses to trastuzumab deruxtecan (T-Dxd) in HER2 IHC spectrum 2+ versus 3+ urothelial carcinoma across lines of therapy.
4581 Background: The role of HER2 as a therapeutically actionable target has been validated with the DESTINY-PanTumor02 tr...
Real-world treatment patterns and clinical outcomes among cholangiocarcinoma patients treated with futibatinib or pemigatinib.
4109 Background: Pemigatinib and futibatinib are FGFR2 inhibitors approved by the US Food and Drug Administration in 2020...
Phase 1 study of VLPONC-01, a novel IL-12–encoding saRNA viral replicon particle, alone and in combination with pembrolizumab in head and neck cancer patients: Protocol summary.
TPS6134 Background: Head and neck squamous cell carcinoma (HNSCC) has high recurrence rates despite standard perioperative...
Integrating metabolic response and circulating tumor biomarkers as early indicators of therapy outcome in locally advanced inoperable rectal cancer.
e15523 Background: The integration of immunotherapy with chemotherapy in locally advanced rectal cancer (LARC) is a standa...
Rapid AI-assisted intraoperative diagnosis for biliary tract adenocarcinoma using femtosecond laser label-free microscopy.
e16019 Background: Intraoperative histopathological assessment is crucial in hepatobiliary surgery, particularly for deter...
Comparative real-world outcomes with talquetamab and teclistamab in relapsed/refractory multiple myeloma: A TriNetX observational study.
e19519 Background: Talquetamab (GPRC5D) and teclistamab (BCMA) are bispecific antibodies for relapsed/refractory multiple...
YL205, a novel anti-Napi2b antibody drug conjugate (ADC), in patients with ovarian cancer: Preliminary result from a first-in-human trial.
5551 Background: Sodium-dependent phosphate transport protein 2b (NaPi2b) is a rapidly internalizing sodium-phosphate tran...
Outcomes of combined HCC-cholangiocarcinoma with adjuvant chemotherapy: An NCDB cohort.
4166 Background: Combined (or mixed) hepatocellular carcinoma-cholangiocarcinomas (cHCC-CCA) are rare liver tumors that ar...
Global cancer mortality attributable to armed conflict: A GBD 1990–2021 analysis.
e23239 Background: Armed conflict disrupts cancer prevention, diagnosis, and treatment continuity, yet its contribution to...
A large prospective patient-advocacy assessment of fears, concerns, and challenges in patients diagnosed with lung cancer in the United States.
8073 Background: Studies have been conducted assessing patient (pt) experiences with lung cancer, but minimal data is avai...